As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Amicus Therapeutics, Inc. The largest reported stake is Barclays PLC's, at 5.65%. 13 filings are on record since August 14, 2025 (Schedule 13G, May 14, 2026).
Sell to companies like Amicus Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: The Goldman Sachs Group, Inc. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Barclays PLC · Sole voting: 17,747,658 · Shared voting: 8,014 · Sole dispositive: 17,747,658 · Shared dispositive: 8,014 · SCHEDULE 13G, 2026-05-14
- · Holder: The Goldman Sachs Group, Inc. · Percent: 5.3% · SCHEDULE 13G
- · Reporting person: UBS Group AG · Sole voting: 0 · Shared voting: 17,071,007 · Sole dispositive: 0 · Shared dispositive: 14,222,423 · SCHEDULE 13G, 2026-05-07
- · Holder: Glazer Capital, LLC · Percent: 0% · SCHEDULE 13G
Amicus Therapeutics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Barclays PLC | 5.65% | 17,755,672 | SCHEDULE 13G, 2026-05-14 | 2026-03-31 |
| UBS Group AG | 5.5% | 17,141,817 | SCHEDULE 13G, 2026-05-07 | 2026-03-31 |
| Vanguard Capital Management | 5.2% | 16,350,837 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Avoro Capital Advisors LLC | 4.87% | 15,025,000 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| William Blair Investment Management, LLC | 3.4% | 10,627,717 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
| Perceptive Advisors LLC | 2.4% | 7,412,830 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Wellington Management Group LLP | 0.4% | 1,373,867 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
| Glazer Capital, LLC | 0% | 0 | SCHEDULE 13G, 2026-05-01 | 2026-04-24 |
| The Goldman Sachs Group, Inc. | 0% | 0 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
Holding shares or following this stake? See who's behind Amicus Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Amicus Therapeutics, Inc. and the records around it.
Amicus Therapeutics, Inc. elsewhere on the record
- Acquisition Apr 2026
- Who owns it
Companies that share a holder
- UBS Group AG also filed stake reports on 13 other companies: Freight Technologies, Inc. (Nov 2026), Rising Dragon Acquisition Corp. (Nov 2026), Starlink AI Acquisition Corp (Nov 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC also filed stake reports on 21 other companies: Baldwin Insurance Group, Inc. (Nov 2026), GeneDx Holdings Corp. (Nov 2026), i3 Verticals, Inc. (Aug 2026)
Watch Amicus Therapeutics, Inc.
Get an email when Amicus Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Amicus Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Amicus Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amicus Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Barclays PLC | 17,747,658 | 8,014 | 17,747,658 | 8,014 | SCHEDULE 13G, 2026-05-14 |
| UBS Group AG | 0 | 17,071,007 | 0 | 14,222,423 | SCHEDULE 13G, 2026-05-07 |
| The Goldman Sachs Group, Inc. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-12 |
| Goldman Sachs & Co. LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Amicus Therapeutics, Inc. by CUSIP 03152W109 and gives its principal executive office as 47 HULFISH STREET, PRINCETON (SCHEDULE 13G/A, 2026-08-12).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Perceptive Advisors LLC | 2.4% | SCHEDULE 13G/A |
| 2025-11-12 | William Blair Investment Management, LLC | 5.2% | SCHEDULE 13G |
| 2025-11-14 | Avoro Capital Advisors LLC | 4.87% | SCHEDULE 13G/A |
| 2025-12-03 | The Vanguard Group | 10% | SCHEDULE 13G/A |
| 2026-02-09 | William Blair Investment Management, LLC | 3.4% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 0.4% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-29 | Vanguard Capital Management | 5.2% | SCHEDULE 13G |
| 2026-05-01 | Glazer Capital, LLC | 0% | SCHEDULE 13G |
| 2026-05-07 | UBS Group AG | 5.5% | SCHEDULE 13G |
| 2026-05-11 | The Goldman Sachs Group, Inc. | 5.3% | SCHEDULE 13G |
| 2026-05-14 | Barclays PLC | 5.65% | SCHEDULE 13G |
| 2026-08-12 | The Goldman Sachs Group, Inc. | 0% | SCHEDULE 13G/A |
Questions about who owns Amicus Therapeutics, Inc.
Who owns Amicus Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Amicus Therapeutics, Inc.: Barclays PLC (5.65%, Schedule 13G, filed 2026-05-14), UBS Group AG (5.5%, Schedule 13G, filed 2026-05-07) and Vanguard Capital Management (5.2%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Amicus Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Amicus Therapeutics, Inc. on this page are Barclays PLC (5.65%), UBS Group AG (5.5%) and Vanguard Capital Management (5.2%).
When did Barclays PLC buy into Amicus Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Barclays PLC on this page is the Schedule 13G, filed 2026-05-14, reporting 5.65%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Amicus Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 27, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| December 19, 2025 | Acquired by BioMarin Pharmaceutical Inc. | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Amicus Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.